EGFR and neoplasm: In this series of patients with advanced lung adenocarcinoma and EGFR-sensitive mutations who were treated with EGFR TKIs, CEA could be used as a significant predictive and prognostic tumor marker when selected 10 ng/ml as cut off point of pretreatment serum CEA levels.